Repeat intradetrusor injections of onabotulinum toxin A for refractory idiopathic overactive bladder patients: A single-center experience

Female Pelvic Medicine and Reconstructive Surgery

Volumn 17, Issue 5, 2011, Pages 253-257

  Gousse, Angelo E ^a   Kanagarajah, Prashanth ^b   Ayyathurai, Rajinikanth ^b   Handa, Priyanka ^b   Dabas, Nikita ^b   Gomez, Christopher S ^b  

^a FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Incontinence; Intradetrusor injection; Onabotulinum toxin A; Overactive bladder; Quality of life

Indexed keywords

REFRACTORY MATERIALS;

INCONTINENCE; ONABOTULINUM TOXIN A; OVERACTIVE BLADDER; QUALITY OF LIFE; RANDOMIZED TRIAL; VISUAL ANALOG SCALE;

TOXIC MATERIALS;

EID: 80052989375     PISSN: 21518378     EISSN: None     Source Type: Journal    
DOI: 10.1097/SPV.0b013e31822f816f     Document Type: Article

References (21)

1. Ganz ML, Smalarz AM, Krupski TL, et al. Economic costs of overactive bladder in the United States. Urology 2009;6:96.
2. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167-178. (Pubitemid 34195211)
3. Campbell JD, Gries KS, Watanabe JH, et al. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: a review of published evidence. BMC Urol 2009;9:18.
4. Glinski RW, Siegel S. Refractory overactive bladder: beyond oral anticholinergic therapy. Indian J Urol 2007;23:166-173.
5. Schurch B, Stöhrer M, Kramer G, et al. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000;164:692-697. (Pubitemid 30637604)
6. Schurch B, de Sèze M, Denys P, et al. Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005;174:196-200. (Pubitemid 40825713)
7. Ehren I, Volz D, Farrelly E, et al. Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study. Scand J Urol Nephrol 2007;41:335-340. (Pubitemid 47357195)
8. Mohanty NK, Nayak RL, Alam M, et al. Role of botulinum toxin-A in management of refractory idiopathic detrusor overactive bladder: single center experience. Indian J Urol 2008;24:182-185.
9. Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006;176:177-185. (Pubitemid 43815416)
10. Sahai A, Khan MS, Dasgupta P. Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial. J Urol 2007;177:2231-2236. (Pubitemid 46726400)
11. Brubaker L, Richter HE, Visco A, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-222.
12. Yablon SA, Brashear A, Gordon MF, et al. Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of postroke spasticity: a pooled-data analysis of three clinical trials. Clin Ther 2007;29:683-690. (Pubitemid 47016643)
13. Cohen BL, Rivera R, Barboglio P, et al. Safety and tolerability of sedation-free flexible cystoscopy for intradetrusor botulinum toxin-A injection. J Urol 2007;177:1006-1010. (Pubitemid 46216355)
14. Khan S, Kessler TM, Apostolidis A, et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. J Urol 2009;181:1773-1778.
15. Khan S, Panicker J, Roosen A, et al. Complete continence after botulinum neurotoxin type A injections for refractory idiopathic detrusor overactivity incontinence: patient-reported outcome at 4 weeks. Eur Urol 2009;4:20.
16. Sahai A, Dowson C, Khan MS, et al. Improvement in quality of life after botulinum toxin-A injections for idiopathic detrusor overactivity: results from a randomized double-blind placebo-controlled trial. BJU Int 2009;103:1509-1515.
17. Brubaker L, Richter HE, Visco A, et al. Pelvic Floor Disorders Network. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217-222.
18. Chapple C, De Ridder D. The second-line management of idiopathic overactive bladder: what is the place of sacral neuromodulation and botulinum toxin-A in contemporary practice? BJU Int 2009;104:1188-1190.
19. Ashok K, Wang A. Detrusor overactivity: an overview. Arch Gynecol Obstet 2010;282:33-41.
20. Bael A, Verhulst J, Lax H, et al. Investigator bias in urodynamic studies for functional urinary incontinence. J Urol 2009;182:1949-1952.
21. Sahai A, Dowson C, Khan MS, et al. Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity. Urology 2010;75:552-558.